Cover Image
市場調查報告書

自體免疫疾病診斷藥:全球市場

Autoimmune Disease Diagnostics: Global Markets

出版商 BCC Research 商品編碼 311756
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
自體免疫疾病診斷藥:全球市場 Autoimmune Disease Diagnostics: Global Markets
出版日期: 2014年09月04日 內容資訊: 英文 128 Pages
簡介

全球自體免疫疾病診斷藥市場2013年達119億美元規模。該市場預計2014年達121億美元,2019年達131億美元,2014∼2019年的年複合成長率是以1.6%擴大。

本報告提供全球自體免疫疾病診斷藥市場概要、2014年、2019年的市場趨勢預測、各地區、疾病、性別趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 自體免疫疾病概要

  • 自體免疫疾病的原因
    • 內在因素
    • 環境因素

第4章 自體免疫疾病診斷藥概要

  • 簡介
  • 現在使用的技術
  • 間接的免疫螢光法
  • 酵素免疫吸附法
  • 免疫印漬術
  • LINE BLOT法
  • 複合的免疫檢測法
  • 凝集作用
  • 二元免疫擴散法
  • 相對免疫電泳法
  • 自體免疫抗體檢測的效能手法的摘要
  • 各企業銷售的自體免疫產品
  • 自體免疫診斷藥的新興技術

第5章 全球自體免疫疾病診斷藥市場

  • 方法
  • 市場規模
  • 類風濕性關節炎
  • 發炎性腸道疾病
  • 第一型糖尿病
  • 多發性硬化症
  • 全身性紅斑狼瘡

第6章 產業分析

  • 需求連鎖分析
  • 供應鏈分析

第7章 來自政府的法規

  • 歐洲法規
  • 北美各國的法律規章
  • 南美的法律規章
  • 亞洲的法律規章
  • 大洋洲的法律規章
  • 未來趨勢

第8章 產業主要的課題

  • 檢驗結果的標準化
  • 患者對自體免疫併發症的認識不足
  • 實施診斷化驗的熟練技術人員不足
  • 製造商

第9章 專利分析

第10章 企業簡介

第11章 附錄:合併、收購

圖表

目錄
Product Code: PHM160A

REPORT HIGHLIGHTS

The global market value for autoimmune disease diagnostics for 2013 was valued at $11.9 billion. This is expected to reach about $12.1 billion in 2014 and $13.1 billion in 2019, with a compound annual growth rate (CAGR) of 1.6% for the five-year period, 2014 to 2019.

This report provides:

  • An overview of the global market for autoimmune disease diagnostics.
  • Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
  • Segmentation of the market by disease, by geographical location, and by gender.
  • Industry analysis with focuses on customers, suppliers, competitors, new entrants, substitutes, and complements.
  • Comprehensive company profiles of major players in the industry.

SCOPE OF REPORT

The report provides a thorough background of the structure of the market and outlines the chief challenges and opportunities it faces. This report estimates the global diagnostics market for autoimmune diseases. Market size for the years 2012, 2013, 2014 and 2019 is presented. In addition, market size by various segments, namely geographic regions, gender and disease phase (pre-treatment and in-treatment) is included.

Market size estimates for pre-treatment and during-treatment phases are presented. The pre-treatment and during-treatment analyses consider the complete spectrum of tests available, including autoimmune-specific tests and complementary tests such as routine blood analyses. The estimates also include ex-vivo diagnostics techniques such as X-ray and other imaging-based techniques.

Certain autoimmune disorders are more prevalent than others and form the bulk of the diseases. This report covers the market specifically for these more prevalent disorders, namely:

  • Rheumatoid arthritis.
  • Inflammatory bowel disease.
  • Type 1 diabetes.
  • Multiple sclerosis.
  • Systemic lupus erythematous (SLE).

ANALYST CREDENTIALS

Anandi Karumbati is the BCC Research analyst for this report. She holds a degree in Pharmacy from Birla Institute of Technology and Sciences (India) and a Ph.D. in Toxicology from the University of Kentucky (U.S). She has five years of post doctoral training in genetics and biochemistry from the University of Michigan and has worked for three years at ReaMetrix Pvt Ltd., a diagnostics company in India. She is currently Lead Scientist at the Centre for Cellular and Molecular Platforms (India).

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR AUTOIMMUNE DIAGNOSTICS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR AUTOIMMUNE DIAGNOSTICS, 2012-2019 ($ MILLIONS)

CHAPTER 3 - AUTOIMMUNE DISEASE OVERVIEW

  • CAUSES OF AUTOIMMUNE DISEASES
    • INTRINSIC FACTORS
      • Immune Dysfunction
        • TABLE 1: ASSOCIATION OF IMMUNE DYSFUNCTION SYNDROMES ASSOCIATE WITH AUTOIMMUNE DISEASES
      • Gender
      • Age
    • ENVIRONMENTAL FACTORS
      • TABLE 2: INFECTIOUS ETIOLOGIES OF SELECTED AUTOIMMUNE DISEASES
      • Lifestyle Factors
        • TABLE 3: LIST OF AUTOIMMUNE AND AUTOIMMUNE RELATED DISEASES
        • FIGURE 1: U.S. PREVALENCE OF SELECTED AUTOIMMUNE DISEASES (NUMBER OF CASES PER 100,000)

CHAPTER 4 - OVERVIEW OF AUTOIMMUNE DISEASE DIAGNOSTICS

  • INTRODUCTION
    • TABLE 4: AUTOANTIBODIES AND ASSOCIATED DISEASES
  • TECHNOLOGIES CURRENTLY USED FOR AUTOIMMUNE DISEASE DIAGNOSIS
    • TABLE 5: COMMON TECHNOLOGIES USED IN AUTOIMMUNE DIAGNOSTICS
  • INDIRECT IMMUNOFLUORESCENCE (IIF-ANA)
    • Indications
    • Methodology
      • FIGURE 2: IIF-ANA TEST METHODOLOGY
    • Test Results
      • TABLE 6: ANA PATTERNS AND ASSOCIATED DISEASES
    • Advantages and Limitations of the IIF-ANA Test
      • TABLE 7: CONDITIONS ASSOCIATED WITH POSITIVE IIF-ANA RESULTS
  • ENZYME-LINKED IMMUNOABSORBENT ASSAY (ELISA) FOR ANA
    • Indication
    • Methodology
      • FIGURE 3: ELISA METHODOLOGY
    • Advantages and Limitations of the ELISA Assay for ANA
  • WESTERN BLOT FOR ANA
    • Indications
    • Methodology
      • FIGURE 4: WESTERN BLOT METHODOLOGY
    • Test Results
    • Advantages and Limitations of the Western Blot assay for ANA
  • DOT BLOT
    • Indications
    • Methodology
    • Test Results
      • FIGURE 5: DOT BLOT TEST ASSAY METHODOLOGY
    • Advantages and Limitations of the Dot Blot Assay
  • LINE BLOT
    • Indications
    • Methodology
    • Test Results
      • FIGURE 6: ANA LINE ASSAY METHODOLOGY
    • Advantages and Limitations of the Line Blot Assay for ANA
  • MULTIPLEX IMMUNOASSAY
    • Flow cytometry
      • Indications
      • Methodology
      • Test Results
        • FIGURE 7: ANA FLOW CYTOMETRY ASSAY METHODOLOGY
      • Advantages and Limitations of the Flow Cytometry for ANA
    • Microarray
      • Indications
      • Methodology
      • Advantages and Limitations of Microarray for ANA
  • AGGLUTINATION
    • Indications
    • Methodology
      • FIGURE 8: ANA AGGLUTINATION ASSAY METHODOLOGY
    • Advantages and Limitations of Agglutination for ANA
  • DOUBLE IMMUNE DIFFUSION (DID)
    • Indications
    • Methodology
      • FIGURE 9: ANA DOUBLE IMMUNE DIFFUSION ASSAY METHODOLOGY
    • Advantages and Limitations of Double Immune Diffusion for ANA
  • COUNTERIMMUNOELECTROPHORESIS (CIEP)
    • Indication
    • Methodology
      • FIGURE 10: COUNTERIMMUNOELECTROPHORESIS METHODOLOGY
    • Advantages and Limitations of Counterimmunoelectrophoresis for ANA
  • SUMMARY OF PERFORMANCE METHODS IN THE DETECTION OF AUTOIMMUNE ANTIBODIES
    • TABLE 8: PERFORMANCE OF LABORATORY METHODS IN DETECTION OF AUTOIMMUNE ANTIBODIES
  • AUTOIMMUNE PRODUCTS SOLD BY COMPANIES
    • TABLE 9: AUTOIMMUNE PRODUCTS SOLD BY SELECTED MULTINATIONAL COMPANIES, BY TECHNOLOGY
    • TABLE 10: PRODUCTS SOLD BY SELECTED AUTOIMMUNE-SPECIALIZED COMPANIES, BY TECHNOLOGY
  • EMERGING TECHNOLOGIES IN AUTOIMMUNE DIAGNOSTICS
    • BIOINFORMATICS
      • Companies and Research Institutes Using Bioinformatics
    • BIOMARKERS
      • Companies and Research Institutes Using Biomarkers
    • APPLICATIONS FOR MOBILE PHONES
    • LAB AUTOMATION

CHAPTER 5 - GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET

  • METHODOLOGY
    • FIGURE 11: GLOBAL PREVALENCE OF THE FIVE MAJOR AUTOIMMUNE DISEASES
    • FIGURE 12: GLOBAL INCIDENCE OF THE FIVE MAJOR AUTOIMMUNE DISEASES
  • MARKET SIZE
    • PRE-TREATMENT MARKET
      • TABLE 11: MARKET SIZE FOR PRE-TREATMENT PANEL BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 12: MARKET SIZE FOR PRE-TREATMENT AUTOIMMUNE SPECIFIC TESTS BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 13: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 13: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR ALL DISEASES BY REGION, 2019 ($ MILLIONS)
      • TABLE 14: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL BY GENDER, THROUGH 2019 ($ MILLIONS)
    • DURING-TREATMENT MARKET
      • TABLE 15: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTICS BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 16: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTICS BY REGION, THROUGH 2019 ($ MILLIONS)
  • RHEUMATOID ARTHRITIS
    • CLINICAL BACKGROUND
    • CLINICAL MANIFESTATIONS AND SYMPTOMS
      • TABLE 17: CLASSIFICATION OF RHEUMATOID ARTHRITIS
    • CURRENT BIOMARKERS TO DIAGNOSE RHEUMATOID ARTHRITIS
    • LABORATORY TESTS
      • FIGURE 14: FREQUENCY OF ORDERING MULTIPLE AUTOANTIBODY TESTS FOR RHEUMATOID ARTHRITIS DIAGNOSIS (%)
    • MARKET SIZE
      • TABLE 18: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 15: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY REGION, 2019 ($ MILLIONS)
      • TABLE 19: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY GENDER, THROUGH 2019 ($ MILLIONS)
      • TABLE 20: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 21: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF RHEUMATOID ARTHRITIS BY REGION, THROUGH 2019 ($ MILLIONS)
      • TABLE 22: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF RHEUMATOID ARTHRITIS BY GENDER, THROUGH 2019 ($ MILLIONS)
    • COMPANIES SUPPLYING DIAGNOSTIC KITS
      • TABLE 23: SELECTED COMPANIES OFFERING DIAGNOSTIC KITS FOR RHEUMATOID ARTHRITIS
  • INFLAMMATORY BOWEL DISEASE
    • CLINICAL BACKGROUND
    • CLINICAL MANIFESTATIONS AND SYMPTOMS
    • MARKET SIZE
      • TABLE 24: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 16: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY REGION, 2019 ($ MILLIONS)
      • TABLE 25: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY GENDER, THROUGH 2019 ($ MILLIONS)
      • TABLE 26: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 27: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF IBD BY REGION, THROUGH 2019 ($ MILLIONS)
      • TABLE 28: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF IBD BY GENDER, THROUGH 2019 ($ MILLIONS)
    • CURRENT BIOMARKERS FOR IBD
      • TABLE 29: CURRENT BIOMARKERS FOR IBD DIAGNOSIS AND CLASSIFICATION
    • EMERGING BIOMARKERS
    • LABORATORY TESTS
    • COMPANIES OFFERING TESTS FOR IBD
      • TABLE 30: COMPANIES WITH TESTS FOR INFLAMMATORY BOWEL DISEASE DIFFERENTIAL DIAGNOSIS
  • TYPE 1 DIABETES
    • CLINICAL BACKGROUND
    • CLINICAL MANIFESTATIONS AND SYMPTOMS
      • Symptoms
    • CURRENT BIOMARKERS FOR TYPE 1 DIABETES
    • EMERGING BIOMARKERS
    • LABORATORY TESTS
    • MARKET SIZE
      • TABLE 31: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF TYPE 1 DIABETES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 17: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF TYPE 1 DIABETES BY REGION, 2019 ($ MILLIONS)
      • TABLE 32: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR TYPE 1 DIABETES BY GENDER, THROUGH 2019 ($ MILLIONS)
      • TABLE 33: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR TYPE 1 DIABETES BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 34: MARKET SIZE FOR DIAGNOSTIC DURING-TREATMENT OF TYPE 1 DIABETES BY REGION, THROUGH 2019 ($ MILLIONS)
      • TABLE 35: MARKET SIZE FOR DIAGNOSTIC DURING-TREATMENT OF TYPE 1 DIABETES BY GENDER, THROUGH 2019 ($ MILLIONS)
    • COMPANIES OFFERING TESTS FOR TYPE 1 DIABETES
      • TABLE 36: SELECTED COMPANIES WITH TESTS FOR TYPE 1 DIABETES DIFFERENTIAL DIAGNOSIS
  • MULTIPLE SCLEROSIS
    • CLINICAL BACKGROUND
    • CLINICAL MANIFESTATIONS AND SYMPTOMS
    • CURRENT BIOMARKERS
    • EMERGING BIOMARKERS
    • LABORATORY TESTS
    • MARKET SIZE
      • TABLE 37: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 18: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY REGION, 2019 ($ MILLIONS)
      • TABLE 38: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY GENDER, THROUGH 2019 ($ MILLIONS)
      • TABLE 39: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 40: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY REGION, THROUGH 2019 ($ MILLIONS)
      • TABLE 41: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY GENDER, THROUGH 2019 ($ MILLIONS)
    • COMPANIES SUPPLYING DIAGNOSTIC KITS FOR MS
      • TABLE 42: SELECTED COMPANIES OFFERING DIAGNOSTIC KITS FOR MS
  • SYSTEMIC LUPUS ERYTHEMATOSUS
    • CLINICAL BACKGROUND
    • SYMPTOMS
    • CURRENT BIOMARKERS
    • LABORATORY TESTS
    • MARKET SIZE
      • TABLE 43: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF SLE BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 19: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF SLE BY REGION, 2019 ($ MILLIONS)
      • TABLE 44: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR SLE BY GENDER, THROUGH 2019 ($ MILLIONS)
      • TABLE 45: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF SLE BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
      • TABLE 46: MARKET SIZE FOR DIAGNOSTIC PANEL DURING-TREATMENT OF SLE BY REGION, THROUGH 2019 ($ MILLIONS)
      • TABLE 47: MARKET SIZE FOR DIAGNOSTIC DURING-TREATMENT OF SLE BY GENDER, THROUGH 2019 ($ MILLIONS)
    • COMPANIES OFFERING DIAGNOSTIC KITS FOR SLE
      • TABLE 48: COMPANIES WITH DIAGNOSTIC KITS FOR SLE

CHAPTER 6 - INDUSTRY ANALYSES

  • TABLE 49: AUTOIMMUNE DISEASE DIAGNOSTICS INDUSTRY VALUE CHAIN
  • DEMAND CHAIN ANALYSIS
    • CUSTOMERS (PATIENTS)
      • TABLE 50: PER CAPITA HEALTH EXPENDITURE BY REGION ($)
      • FIGURE 20: PER CAPITA MEAN HEALTH EXPENDITURE BY REGION ($)
    • PAYERS
      • TABLE 51: PERCENTAGE OF HEALTH EXPENDITURES IN ASIA, BY PAYER TYPE, 2013 (%)
      • TABLE 52: PERCENTAGE OF HEALTH EXPENDITURES IN AFRICA, BY PAYER TYPE, 2013 (%)
      • TABLE 53: PERCENTAGE OF HEALTH EXPENDITURES IN CENTRAL AMERICA, BY PAYER TYPE, 2013 (%)
      • TABLE 54: PERCENTAGE OF HEALTH EXPENDITURES IN NORTH AMERICA, BY PAYER TYPE, 2013 (%)
      • TABLE 55: PERCENTAGE OF HEALTH EXPENDITURES IN SOUTH AMERICA, BY PAYER TYPE, 2013 (%)
      • TABLE 56: PERCENTAGE OF HEALTH EXPENDITURES IN EUROPE, BY PAYER TYPE, 2013 (%)
      • TABLE 57: PERCENTAGE OF HEALTH EXPENDITURES IN THE MIDDLE EAST, BY PAYER TYPE, 2013 (%)
      • TABLE 58: PERCENTAGE OF HEALTH EXPENDITURES IN OCEANIA, BY PAYER TYPE, 2013 (%)
      • FIGURE 21: SUMMARY CHART OF PROPORTION OF HEALTH EXPENDITURES BY PAYER TYPE, BY REGION, 2013 (%)
      • FIGURE 22: PAYER TYPE BY COUNTRY INCOME LEVEL, 2013 (%)
  • SUPPLY CHAIN ANALYSIS
    • LABORATORIES
      • TABLE 59: MAJOR INDEPENDENT LABORATORIES BY REVENUE AND NUMBER OF EMPLOYEES, 2013
      • TABLE 60: COMPARISON OF MARGIN AND COST STRUCTURE OF DIAGNOSTICS LABS FOR SELECTED COUNTRIES (%)
    • MANUFACTURERS
      • TABLE 61: MAJOR MANUFACTURERS OF AUTOIMMUNE DISEASE DIAGNOSTICS BY REVENUE* AND NUMBER OF EMPLOYEES, 2013

CHAPTER 7 - GOVERNMENT REGULATIONS

  • EUROPEAN REGULATIONS
  • REGULATION IN NORTH AMERICAN COUNTRIES
    • U.S. REGULATIONS
      • TABLE 62: DIFFERENCES BETWEEN U.S. AND EUROPEAN GOVERNMENT REGULATIONS FOR MEDICAL DEVICES
    • CANADIAN REGULATIONS
  • REGULATION IN SOUTH AMERICA
  • REGULATION IN ASIA
    • TABLE 63: REGULATION OF MEDICAL DIAGNOSTICS IN SELECTED ASIAN COUNTRIES
  • REGULATION IN OCEANIA
  • FUTURE REGULATORY TRENDS

CHAPTER 8 - KEY CHALLENGES IN THE INDUSTRY

  • STANDARDIZATION OF TEST RESULTS
  • LACK OF AWARENESS AMONG PATIENTS OF AUTOIMMUNE COMPLICATIONS
  • SHORTAGE OF SKILLED TECHNICIANS FOR PERFORMING DIAGNOSTIC ASSAYS
    • TABLE 64: CHALLENGES FACED BY IMMUNOASSAY KIT/ INSTRUMENT
  • MANUFACTURERS
    • TABLE 65: CHALLENGES FACED BY IMMUNOASSAY CLINICAL LABORATORIES
    • TABLE 66: IMMUNOASSAY CHALLENGES FACED BY PHYSICIANS

CHAPTER 9 - PATENT ANALYSES

  • PATENTS BY DISEASE TYPE
    • TABLE 67: PATENTS RELATED TO TYPE 1 DIABETES, 2007-2013
    • TABLE 68: PATENTS RELATED TO MULTIPLE SCLEROSIS, 2011
    • TABLE 69: PATENTS RELATED TO IRRITABLE BOWEL SYNDROME, 2001-FEB 2014
    • TABLE 70: PATENTS RELATED TO SYSTEMIC LUPUS ERYTHEMATOSUS, 2008-2012
    • TABLE 71: PATENTS RELATED TO RHEUMATOID ARTHRITIS, 1995-2011
  • SELECTED PATENTS BY MANUFACTURER
    • PATENTS BY MULTINATIONAL COMPANIES
      • Abbott
        • TABLE 72: ABBOTT PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2008 AND 2012
      • Bio-rad
        • TABLE 73: BIO-RAD PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2002-2013
      • Biomerieux
        • TABLE 74: BIOMERIEUX PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2012 AND 2013
      • Hitachi
        • TABLE 75: HITACHI PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2000
      • Life Technologies
        • TABLE 76: LIFE TECHNOLOGIES PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2012
      • Roche
        • TABLE 77: ROCHE PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2014
      • Siemens Healthcare
        • TABLE 78: SIEMENS HEALTHCARE PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2013
      • Thermo Fisher (Phadia)
        • TABLE 79: THERMO FISHER PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2008-2013
    • PATENTS BY AUTOIMMUNE SPECIALIZED COMPANY
      • Aesku
        • TABLE 80: AESKU PATENTS FOR NOVEL BIOMARKERS, 2010 AND 2013
        • TABLE 81: AESKU PATENTS FOR DIAGNOSTIC METHODS, 2013
      • Euroimmun
        • TABLE 82: EUROIMMUN PATENTS FOR NOVEL BIOMARKERS, 2009-2013
        • TABLE 83: EUROIMMUN PATENTS FOR DIAGNOSTIC METHODS, 2013 AND 2014
    • IMMCO
      • TABLE 84: IMMCO PATENTS FOR NOVEL BIOMARKERS, 2004 AND 2008
      • TABLE 85: IMMCO PATENTS FOR DIAGNOSTIC METHODS, 2011
      • Inova
        • TABLE 86: INOVA PATENTS RELATED TO AUTOIMMUNE DIAGNOSTICS, 2008-2013
      • Orgentec Diagnostika
        • TABLE 87: ORGENTEC DIAGNOSTIKA PATENTS RELATED TO AUTOIMMUNE DIAGNOSTICS, 2011 AND 2013

CHAPTER 10 - COMPANY PROFILES

  • COMPANY LISTINGS
    • ABBOTT
      • TABLE 88: FINANCIAL DETAILS OF ABBOTT, 2011-2013 ($ MILLIONS/%)
    • BECTON DICKINSON
      • TABLE 89: FINANCIAL DETAILS OF BECTON DICKINSON, 2011-2013 ($ MILLIONS/%)
    • BIOMERIEUX SA
      • TABLE 90: FINANCIAL DETAILS OF BIOMERIEUX, 2010-2012 (MILLIONS/%)
    • BIO-RAD
      • TABLE 91: FINANCIAL DETAILS OF BIO-RAD, 2010-2012 ($ MILLIONS/%)
    • BIO REFERENCE LABS
      • TABLE 92: FINANCIAL DETAILS OF BIO REFERENCE, 2011-2013 ($ MILLIONS/%)
    • DANAHER CORP.
      • TABLE 93: FINANCIAL DETAILS OF DANAHER, 2011-2013 ($ MILLIONS/%)
    • HEMAGEN DIAGNOSTICS
      • TABLE 94: FINANCIAL DETAILS OF HEMAGEN DIAGNOSTICS, 2010-2012 ($ MILLIONS/%)
    • LABCORP
      • TABLE 95: FINANCIAL DETAILS OF LABCORP, 2011-2013 ($ MILLIONS/%)
    • QUEST DIAGNOSTICS
      • TABLE 96: FINANCIAL DETAILS OF QUEST DIAGNOSTICS, 2011-2013 ($ MILLIONS/%)
    • ROCHE HOLDINGS
      • TABLE 97: FINANCIAL DETAILS OF ROCHE, 2011-2013 ($ MILLIONS/%)
    • SIEMENS HEALTHCARE DIAGNOSTICS
      • TABLE 98: FINANCIAL DETAILS OF SIEMENS HEALTHCARE, 2011-2013 (MILLIONS/%)
    • SONIC HEALTHCARE
      • TABLE 99: FINANCIAL DETAILS OF SONIC HEALTHCARE, 2011-2013 (AU$ MILLIONS/%)
    • THERMO FISHER (TMO)
      • TABLE 100: FINANCIAL DETAILS OF THERMO FISHER, 2011-2013 ($ MILLIONS/%)
    • TRINITY BIOTECH GROUP (IMMCO DIAGNOSTICS)
      • TABLE 101: FINANCIAL DETAILS OF TRINITY BIOTECH, 2011-2013 ($ MILLIONS/%)

CHAPTER 11 - APPENDIX: KEY MERGERS AND ACQUISITIONS

  • TABLE 102: KEY MERGERS AND ACQUISITIONS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR AUTOIMMUNE DIAGNOSTICS, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: ASSOCIATION OF IMMUNE DYSFUNCTION SYNDROMES ASSOCIATE WITH AUTOIMMUNE DISEASES
    • TABLE 2: INFECTIOUS ETIOLOGIES OF SELECTED AUTOIMMUNE DISEASES
    • TABLE 3: LIST OF AUTOIMMUNE AND AUTOIMMUNE RELATED DISEASES
    • TABLE 4: AUTOANTIBODIES AND ASSOCIATED DISEASES
    • TABLE 5: COMMON TECHNOLOGIES USED IN AUTOIMMUNE DIAGNOSTICS
    • TABLE 6: ANA PATTERNS AND ASSOCIATED DISEASES
    • TABLE 7: CONDITIONS ASSOCIATED WITH POSITIVE IIF-ANA RESULTS
    • TABLE 8: PERFORMANCE OF LABORATORY METHODS IN DETECTION OF AUTOIMMUNE ANTIBODIES
    • TABLE 9: AUTOIMMUNE PRODUCTS SOLD BY SELECTED MULTINATIONAL COMPANIES, BY TECHNOLOGY
    • TABLE 10: PRODUCTS SOLD BY SELECTED AUTOIMMUNE-SPECIALIZED COMPANIES, BY TECHNOLOGY
    • TABLE 11: MARKET SIZE FOR PRE-TREATMENT PANEL BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 12: MARKET SIZE FOR PRE-TREATMENT AUTOIMMUNE SPECIFIC TESTS BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 13: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 14: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 15: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTICS BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 16: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTICS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 17: CLASSIFICATION OF RHEUMATOID ARTHRITIS
    • TABLE 18: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 19: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 20: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 21: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF RHEUMATOID ARTHRITIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 22: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF RHEUMATOID ARTHRITIS BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 23: SELECTED COMPANIES OFFERING DIAGNOSTIC KITS FOR RHEUMATOID ARTHRITIS
    • TABLE 24: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 25: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 26: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 27: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF IBD BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 28: MARKET SIZE FOR DURING-TREATMENT DIAGNOSIS OF IBD BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: CURRENT BIOMARKERS FOR IBD DIAGNOSIS AND CLASSIFICATION
    • TABLE 30: COMPANIES WITH TESTS FOR INFLAMMATORY BOWEL DISEASE DIFFERENTIAL DIAGNOSIS
    • TABLE 31: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF TYPE 1 DIABETES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR TYPE 1 DIABETES BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 33: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR TYPE 1 DIABETES BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 34: MARKET SIZE FOR DIAGNOSTIC DURING-TREATMENT OF TYPE 1 DIABETES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: MARKET SIZE FOR DIAGNOSTIC DURING-TREATMENT OF TYPE 1 DIABETES BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 36: SELECTED COMPANIES WITH TESTS FOR TYPE 1 DIABETES DIFFERENTIAL DIAGNOSIS
    • TABLE 37: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 38: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 39: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 40: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 41: MARKET SIZE FOR DURING-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 42: SELECTED COMPANIES OFFERING DIAGNOSTIC KITS FOR MS
    • TABLE 43: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF SLE BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 44: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR SLE BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 45: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF SLE BY TEST TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 46: MARKET SIZE FOR DIAGNOSTIC PANEL DURING-TREATMENT OF SLE BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 47: MARKET SIZE FOR DIAGNOSTIC DURING-TREATMENT OF SLE BY GENDER, THROUGH 2019 ($ MILLIONS)
    • TABLE 48: COMPANIES WITH DIAGNOSTIC KITS FOR SLE
    • TABLE 49: AUTOIMMUNE DISEASE DIAGNOSTICS INDUSTRY VALUE CHAIN
    • TABLE 50: PER CAPITA HEALTH EXPENDITURE BY REGION ($)
    • TABLE 51: PERCENTAGE OF HEALTH EXPENDITURES IN ASIA, BY PAYER TYPE, 2013 (%)
    • TABLE 52: PERCENTAGE OF HEALTH EXPENDITURES IN AFRICA, BY PAYER TYPE, 2013 (%)
    • TABLE 53: PERCENTAGE OF HEALTH EXPENDITURES IN CENTRAL AMERICA, BY PAYER TYPE, 2013 (%)
    • TABLE 54: PERCENTAGE OF HEALTH EXPENDITURES IN NORTH AMERICA, BY PAYER TYPE, 2013 (%)
    • TABLE 55: PERCENTAGE OF HEALTH EXPENDITURES IN SOUTH AMERICA, BY PAYER TYPE, 2013 (%)
    • TABLE 56: PERCENTAGE OF HEALTH EXPENDITURES IN EUROPE, BY PAYER TYPE, 2013 (%)
    • TABLE 57: PERCENTAGE OF HEALTH EXPENDITURES IN THE MIDDLE EAST, BY PAYER TYPE, 2013 (%)
    • TABLE 58: PERCENTAGE OF HEALTH EXPENDITURES IN OCEANIA, BY PAYER TYPE, 2013 (%)
    • TABLE 59: MAJOR INDEPENDENT LABORATORIES BY REVENUE AND NUMBER OF EMPLOYEES, 2013
    • TABLE 60: COMPARISON OF MARGIN AND COST STRUCTURE OF DIAGNOSTICS LABS FOR SELECTED COUNTRIES (%)
    • TABLE 61: MAJOR MANUFACTURERS OF AUTOIMMUNE DISEASE DIAGNOSTICS BY REVENUE* AND NUMBER OF EMPLOYEES, 2013
    • TABLE 62: DIFFERENCES BETWEEN U.S. AND EUROPEAN GOVERNMENT REGULATIONS FOR MEDICAL DEVICES
    • TABLE 63: REGULATION OF MEDICAL DIAGNOSTICS IN SELECTED ASIAN COUNTRIES
    • TABLE 64: CHALLENGES FACED BY IMMUNOASSAY KIT/ INSTRUMENT MANUFACTURERS
    • TABLE 65: CHALLENGES FACED BY IMMUNOASSAY CLINICAL LABORATORIES
    • TABLE 66: IMMUNOASSAY CHALLENGES FACED BY PHYSICIANS
    • TABLE 67: PATENTS RELATED TO TYPE 1 DIABETES, 2007-2013
    • TABLE 68: PATENTS RELATED TO MULTIPLE SCLEROSIS, 2011
    • TABLE 69: PATENTS RELATED TO IRRI
    • TABLE BO: EL SYNDROME, 2001-FEB 2014
    • TABLE 70: PATENTS RELATED TO SYSTEMIC LUPUS ERYTHEMATOSUS, 2008--2012
    • TABLE 71: PATENTS RELATED TO RHEUMATOID ARTHRITIS, 1995-2011
    • TABLE 72: ABBOTT PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2008 AND 2012
    • TABLE 73: BIO-RAD PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2002-2013
    • TABLE 74: BIOMERIEUX PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2012 AND 2013
    • TABLE 75: HITACHI PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2000
    • TABLE 76: LIFE TECHNOLOGIES PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2012
    • TABLE 77: ROCHE PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2014
    • TABLE 78: SIEMENS HEALTHCARE PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2013
    • TABLE 79: THERMO FISHER PATENTS RELATED TO AUTOIMMUNE DISEASE DIAGNOSTICS, 2008-2013
    • TABLE 80: AESKU PATENTS FOR NOVEL BIOMARKERS, 2010 AND 2013
    • TABLE 81: AESKU PATENTS FOR DIAGNOSTIC METHODS, 2013
    • TABLE 82: EUROIMMUN PATENTS FOR NOVEL BIOMARKERS, 2009-2013
    • TABLE 83: EUROIMMUN PATENTS FOR DIAGNOSTIC METHODS, 2013 AND 2014
    • TABLE 84: IMMCO PATENTS FOR NOVEL BIOMARKERS, 2004 AND 2008
    • TABLE 85: IMMCO PATENTS FOR DIAGNOSTIC METHODS, 2011
    • TABLE 86: INOVA PATENTS RELATED TO AUTOIMMUNE DIAGNOSTICS, 2008-2013
    • TABLE 87: ORGENTEC DIAGNOSTIKA PATENTS RELATED TO AUTOIMMUNE DIAGNOSTICS, 2011 AND 2013
    • TABLE 88: FINANCIAL DETAILS OF ABBOTT, 2011-2013 ($ MILLIONS/%)
    • TABLE 89: FINANCIAL DETAILS OF BECTON DICKINSON, 2011-2013 ($ MILLIONS/%)
    • TABLE 90: FINANCIAL DETAILS OF BIOMERIEUX, 2010-2012 (MILLIONS/%)
    • TABLE 91: FINANCIAL DETAILS OF BIO-RAD, 2010-2012 ($ MILLIONS/%)
    • TABLE 92: FINANCIAL DETAILS OF BIO REFERENCE, 2011-2013 ($ MILLIONS/%)
    • TABLE 93: FINANCIAL DETAILS OF DANAHER, 2011-2013 ($ MILLIONS/%)
    • TABLE 94: FINANCIAL DETAILS OF HEMAGEN DIAGNOSTICS, 2010-2012 ($ MILLIONS/%)
    • TABLE 95: FINANCIAL DETAILS OF LABCORP, 2011-2013 ($ MILLIONS/%)
    • TABLE 96: FINANCIAL DETAILS OF QUEST DIAGNOSTICS, 2011-2013 ($ MILLIONS/%)
    • TABLE 97: FINANCIAL DETAILS OF ROCHE, 2011-2013 ($ MILLIONS/%)
    • TABLE 98: FINANCIAL DETAILS OF SIEMENS HEALTHCARE, 2011-2013 (MILLIONS/%)
    • TABLE 99 : INANCIAL DETAILS OF SONIC HEALTHCARE, 2011-2013 (AU$ MILLIONS/%)
    • TABLE 100: FINANCIAL DETAILS OF THERMO FISHER, 2011-2013 ($ MILLIONS/%)
    • TABLE 101: FINANCIAL DETAILS OF TRINITY BIOTECH, 2011-2013 ($ MILLIONS/%)
    • TABLE 102: KEY MERGERS AND ACQUISITIONS

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR AUTOIMMUNE DIAGNOSTICS, 2012-2019 ($ MILLIONS)
    • FIGURE 1: U.S. PREVALENCE OF SELECTED AUTOIMMUNE DISEASES (NUMBER OF CASES PER 100,000)
    • FIGURE 2: IIF-ANA TEST METHODOLOGY
    • FIGURE 3: ELISA METHODOLOGY
    • FIGURE 4: WESTERN BLOT METHODOLOGY
    • FIGURE 5: DOT BLOT TEST ASSAY METHODOLOGY
    • FIGURE 6: ANA LINE ASSAY METHODOLOGY
    • FIGURE 7: ANA FLOW CYTOMETRY ASSAY METHODOLOGY
    • FIGURE 8: ANA AGGLUTINATION ASSAY METHODOLOGY
    • FIGURE 9: ANA DOUBLE IMMUNE DIFFUSION ASSAY METHODOLOGY
    • FIGURE 10: COUNTERIMMUNOELECTROPHORESIS METHODOLOGY
    • FIGURE 11: GLOBAL PREVALENCE OF THE FIVE MAJOR AUTOIMMUNE DISEASES
    • FIGURE 12: GLOBAL INCIDENCE OF THE FIVE MAJOR AUTOIMMUNE DISEASES
    • FIGURE 13: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR ALL DISEASES BY REGION, 2019 ($ MILLIONS)
    • FIGURE 14: FREQUENCY OF ORDERING MULTIPLE AUTOANTIBODY TESTS FOR RHEUMATOID ARTHRITIS DIAGNOSIS (%)
    • FIGURE 15: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR RHEUMATOID ARTHRITIS BY REGION, 2019 ($ MILLIONS)
    • FIGURE 16: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR IBD BY REGION, 2019 ($ MILLIONS)
    • FIGURE 17: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF TYPE 1 DIABETES BY REGION, 2019 ($ MILLIONS)
    • FIGURE 18: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL FOR MULTIPLE SCLEROSIS BY REGION, 2019 ($ MILLIONS)
    • FIGURE 19: MARKET SIZE FOR PRE-TREATMENT DIAGNOSTIC PANEL OF SLE BY REGION, 2019 ($ MILLIONS)
    • FIGURE 20: PER CAPITA MEAN HEALTH EXPENDITURE BY REGION ($)
    • FIGURE 21: SUMMARY CHART OF PROPORTION OF HEALTH EXPENDITURES BY PAYER TYPE, BY REGION, 2013 (%)
    • FIGURE 22: PAYER TYPE BY COUNTRY INCOME LEVEL, 2013 (%)
Back to Top